Proposed amendments to the 2027 Budget Law aim to provide 250 million euros for obesity medication reimbursements and 6 million euros for adolescent screening programs.
These measures, announced on November 20, seek to address major gaps in access to long-term care for severe obesity.
The primary amendment, signed by deputies Benigni, Cappellacci, Bagnasco, Patriarca, Casasco, and Mulè, proposes a 250 million euro investment over the 2027-2029 period, according to Sky. This initiative would establish an experimental reimbursement model for patients with a Body Mass Index (BMI) of 40 or higher.
To qualify, patients must also present at least one comorbidity other than diabetes and be deemed eligible for bariatric surgery, yet have shown insufficient response to lifestyle and dietary interventions.
According to iO Donna, the funding is distributed as 50 million euros in 2027, followed by 100 million euros in both 2028 and 2029, according to iO Donna. While the proposal aims to reduce treatment inequalities, the specific active ingredients eligible for reimbursement remain undefined, and prescriptions would be regulated through therapeutic plans managed by the Italian Medicines Agency (AIFA), iO Donna noted.

A second amendment, proposed by Giorgio Mulè, allocates 6 million euros over three years to implement obesity screening for adolescents aged 13 to 19. This plan includes 2 million euros annually to support collaborative efforts between schools and local healthcare networks. The goal is to detect the condition early and initiate preventative care pathways before the onset of more severe health complications.
The Società Italiana dell’Obesità (SIO) has expressed support for both legislative proposals. “Non possiamo accettare che la possibilità di curarsi dipenda dalle condizioni economiche o dal luogo in cui si vive,” said SIO president Silvio Buscemi.
Who would be eligible for the medication reimbursement?
The proposal specifies individuals with a BMI of 40 or greater who suffer from at least one non-diabetic comorbidity and are already candidates for bariatric surgery. The criteria also emphasize those who have not achieved adequate results through traditional diet and lifestyle modifications.
Are these measures currently in effect?
No, these are parliamentary proposals submitted as amendments to the 2027 Budget Law. As of November 20, they have not yet been approved or enacted into law.
What is the objective of the adolescent screening program?
The program aims to foster early detection of obesity within the 13 to 19 age group. By involving schools and local health services, the initiative intends to integrate preventative care into the daily lives of adolescents to mitigate long-term health risks.
The Italian Medicines Agency (AIFA) serves as the national public body responsible for regulating medicines for human use throughout Italy. Operating under the guidance of the Italian Ministry of Health and the supervision of the Ministry of Economy and Finance, the agency manages pharmaceutical expenditure and monitors the entire life cycle of a medicine to ensure its safety and effectiveness.
Beyond its domestic oversight, AIFA is an active participant in the European Medicines Agencies Network, working to harmonize health technology assessments and streamline the path to accessibility for new treatments across Europe.
“È un risultato che attendono le persone con obesità, le loro famiglie e tutti i professionisti sanitari impegnati quotidianamente nella cura di questa malattia,” Buscemi said in closing.
Keep reading